www.novartis.com

Om projektet

Novartis positionerer sig som en virksomhed, der skaber innovative lægemidler. Deres hovedmål er at nytænke medicin for at forlænge folks liv og forbedre deres kvalitet. Hjemmesiden oplyser, at deres lægemidler er tilgængelige for 296 millioner mennesker verden over. Dette er et globalt projekt med fokus på patienter, læger og samfundet som helhed.

Webstedet fungerer som et informationscenter for forskellige brugergrupper. Der er ikke plads til tomme løfter, vægten er lagt på konkrete handlinger: fra kliniske forsøg til finansiel rapportering. Virksomhedens filosofi er enkel: Sammen kan vi ændre spillereglerne i kampen mod alvorlige sygdomme.

Vigtigste retninger

Webstedets indhold er klart opdelt efter publikums interesser. Her er, hvad ressourcen specifikt gør:

• Patienter og plejere. Afsnittet indeholder information om rekruttering til kliniske forsøg, overkommelig adgang til medicinprogrammer, finansieringsmuligheder for patientorganisationer og instruktioner til rapportering af bivirkninger.
• Medicinere. For læger og andre fagfolk er der ressourcer om tilskudsfinansiering, information om kongresser og landespecifikke data.
• Forskning og udvikling (RD). Her er, hvordan banebrydende videnskab bliver til behandlinger af høj værdi.
• Investorer. Afsnit med finansiel information, dataoplysning, begivenheder, aktiekurser og ESG-rapporter.
• Nyheder. Pressemeddelelser, udtalelser, historier og multimedier til journalister.
• Karriere. Afsnit med ledige stillinger, beskrivelse af strategi og virksomhedskultur.

Særskilt værd at nævne er iLive Magazinei - dette er virksomhedens interne magasin, som nu er tilgængeligt i digitalt format. Der udgives historier, podcasts og andet materiale fra organisationens liv.

Funktioner på webstedet

Novartis-webstedet er ikke kun et udstillingsvindue, men et kommunikationsværktøj. Det understøtter mange sprog og regioner, fra Argentina og Brasilien til Japan og Kina. I navigationen kan du finde links til specifikke lande, hvilket indikerer dyb lokalisering af indholdet.

En vigtig del af jobbet er gennemsigtighed. Årsrapporter for 2025 er tilgængelige på hjemmesiden, herunder en rapport om ikke-finansielle forhold. Virksomheden siger også, at det vil udvide produktions- og forskningskapaciteten i USA for at skalere innovation og skabe job.

En anden funktion er vægten på tilgængelighed. Novartis understreger, at værdien af ​​innovation ikke kun ligger i at opdage medicin, men også i at sikre, at de når ud til dem, der har brug for dem, uanset hvor de bor.

Kontaktoplysninger

Der er ingen direkte kontaktnumre eller adresser i den angivne tekst.Siden tilbyder dog klare kommunikationsveje gennem sektionerne Patienter, Healthcare Professionals og Investors. For at finde de oplysninger, du har brug for, findes webstedssøgningsfunktionen på hele webstedet.

Juridiske oplysninger angiver Novartis AG med copyright 2026. Siden er angivet til at være beregnet til et globalt publikum.

• charset: utf-8
• name: description content: Working together, we can reimagine medicine to improve and extend people’s lives.
• name: abstract content: Working together, we can reimagine medicine to improve and extend people’s lives.
• property: og:site_name content: Novartis
• property: og:type content: Website
• property: og:url content: https://www.novartis.com/home
• property: og:title content: Novartis
• property: og:description content: Working together, we can reimagine medicine to improve and extend people’s lives.
• property: og:image content: https://www.novartis.com/sites/novartis_com/files/2023-11/novartis-animated-logo-1x.gif
• property: og:image:url content: https://www.novartis.com/sites/novartis_com/files/2023-11/novartis-animated-logo-1x.gif
• property: og:image:secure_url content: https://www.novartis.com/sites/novartis_com/files/2023-11/novartis-animated-logo-1x.gif
• property: og:image:alt content: Novartis logo
• name: twitter:card content: summary_large_image
• name: twitter:title content: Novartis
• name: twitter:site content: @novartis
• name: twitter:description content: Working together, we can reimagine medicine to improve and extend people’s lives.
• name: twitter:site:id content: 17226612
• name: twitter:creator content: @novartis
• name: twitter:creator:id content: 17226612
• name: twitter:url content: https://www.novartis.com/home
• name: twitter:image content: https://www.novartis.com/sites/novartis_com/files/novartis-logo-open-graph.jpg
• name: twitter:image:alt content: Novartis logo
• name: msvalidate.01 content: 8D3EBDFBAAB1FF3ED7947B6A7DFD293D
• name: google-site-verification content: oWLifsm3cWEQxnH7h2q7auXVJgDapVcYDRjNg1rESi4
• name: MobileOptimized content: width
• name: HandheldFriendly content: true
• name: viewport content: width=device-width, initial-scale=1, shrink-to-fit=no
• equiv: x-ua-compatible content: ie=edge

• Skip to main content
• http://www.novartis.com/
• International
• Americas
• Asia Pacific
• Europe
• Middle East & Africa
• Global |
• Argentina |
• Brazil |
• Canada |
• Canada |
• Andean & CAC |
• Colombia |
• Mexico |
• United States |
• Australia |
• Hong Kong S.A.R. |
• India |
• Indonesia |
• Japan |
• Korea |
• Mainland China |
• Malaysia |
• Philippines |
• Singapore |
• Taiwan |
• Thailand |
• Austria |
• Belgium |
• Belgium |
• Bulgaria |
• Czech Republic |
• Czech Republic |
• Denmark |
• Estonia |
• Finland |
• France |
• Germany |
• Greece |
• Hungary |
• Ireland |
• Italy |
• Latvia |
• Lithuania |
• Netherlands |
• Norway |
• Poland |
• Portugal |
• Romania |
• Russia |
• Serbia |
• Slovakia |
• Slovenia |
• Slovenia |
• Spain |
• Sweden |
• Switzerland |
• Switzerland |
• Türkiye |
• Ukraine |
• United Kingdom |
• Egypt |
• Israel |
• Saudi Arabia |
• South Africa |
• About Novartis
• http://www.novartis.com/about/board-directors
• http://www.novartis.com/about/board-directors/giovanni-caforio
• http://www.novartis.com/about/board-directors/simon-moroney
• http://www.novartis.com/about/board-directors/nancy-c-andrews
• http://www.novartis.com/about/board-directors/ton-buechner
• http://www.novartis.com/about/board-directors/patrice-bula
• http://www.novartis.com/about/board-directors/elizabeth-liz-doherty
• http://www.novartis.com/about/board-directors/ana-de-pro-gonzalo
• http://www.novartis.com/about/board-directors/bridgette-heller
• http://www.novartis.com/about/board-directors/daniel-hochstrasser
• http://www.novartis.com/about/board-directors/frans-van-houten
• http://www.novartis.com/about/board-directors/elizabeth-mcnally
• http://www.novartis.com/about/board-directors/john-d-young
• http://www.novartis.com/about/board-directors/charlotte-pamer-wieser
• http://www.novartis.com/about/executive-committee
• http://www.novartis.com/about/executive-committee/vasant-narasimhan
• http://www.novartis.com/about/executive-committee/shreeram-aradhye
• http://www.novartis.com/about/executive-committee/victor-bulto
• http://www.novartis.com/about/executive-committee/aharon-ronny-gal-phd
• http://www.novartis.com/about/executive-committee/karen-hale
• http://www.novartis.com/about/executive-committee/patrick-horber-md
• http://www.novartis.com/about/executive-committee/harry-kirsch
• http://www.novartis.com/about/executive-committee/rob-kowalski
• http://www.novartis.com/about/executive-committee/steffen-lang
• http://www.novartis.com/about/executive-committee/fiona-marshall
• http://www.novartis.com/about/executive-committee/lutz-hegemann
• http://www.novartis.com/about/executive-committee/teresa-jose
• http://www.novartis.com/about/executive-committee/michelle-weese
• Products
• http://www.novartis.com/about/therapeutic-areas
• Cardiovascular, renal and metabolic
• Immunology
• Neuroscience
• Oncology
• http://www.novartis.com/about/people-and-culture
• http://www.novartis.com/about/inclusion
• http://www.novartis.com/about/inclusion/promoting-inclusion
• http://www.novartis.com/about/inclusion/building-belonging
• http://www.novartis.com/about/inclusion/parental-leave
• http://www.novartis.com/about/inclusion/caring-mental-health-and-wellbeing-our-people
• http://www.novartis.com/about/novartis-gene-therapies
• http://www.novartis.com/about/manufacturing
• http://www.novartis.com/about/quality
• http://www.novartis.com/about/quality/novartis-quality-management-system-qms
• http://www.novartis.com/about/quality/audit-program-and-regulatory-inspections
• http://www.novartis.com/about/quality/product-and-patient-safety-training
• http://www.novartis.com/about/quality/product-recalls
• http://www.novartis.com/about/quality/third-party-suppliers
• http://www.novartis.com/about/novartis-and-european-union
• http://www.novartis.com/about/awards-and-recognition
• Patients and caregivers
• http://www.novartis.com/patients-and-caregivers/novartis-commitment-patients-and-caregivers
• http://www.novartis.com/diseases
• http://www.novartis.com/investors/reporting-and-transparency-hub/patient-organization-funding
• http://www.novartis.com/news/stories/patient-perspectives
• Healthcare professionals
• http://www.novartis.com/healthcare-professionals/medical-congresses-and-events
• http://www.novartis.com/healthcare-professionals/medical-congresses-and-events/asco-annual-meeting
• Pipeline
• http://www.novartis.com/healthcare-professionals/managed-access-programs
• http://www.novartis.com/healthcare-professionals/managed-access-programs/zolgensma-global-managed-access-program-gmap
• http://www.novartis.com/healthcare-professionals/novartis-external-funding
• http://www.novartis.com/healthcare-professionals/healthcare-professional-resources-country
• http://www.novartis.com/healthcare-professionals/investigator-initiated-trials-studies-clinical-and-investigator-initiated-research-non-clinical
• http://www.novartis.com/healthcare-professionals/novartis-medical-information
• http://www.novartis.com/healthcare-professionals/novartis-medical-information/submit-medical-enquiry
• Researchers
• http://www.novartis.com/research-and-development/technology-platforms
• http://www.novartis.com/research-and-development/research-disease-areas
• http://www.novartis.com/research-and-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis
• http://www.novartis.com/research-and-development/research-disease-areas/diseases-aging-and-regenerative-medicine-dare-research-novartis
• http://www.novartis.com/research-and-development/research-disease-areas/dax-exploratory-disease-research-novartis
• http://www.novartis.com/research-and-development/research-disease-areas/global-health-disease-area-research-novartis
• http://www.novartis.com/research-and-development/research-disease-areas/immunology-disease-research-novartis
• http://www.novartis.com/research-and-development/research-disease-areas/neuroscience-research-novartis
• http://www.novartis.com/research-and-development/research-disease-areas/oncology-research-novartis
• http://www.novartis.com/research-and-development/research-collaborations
• http://www.novartis.com/research-and-development/collaborations
• ESG
• Access
• http://www.novartis.com/esg/access/creating-sustainable-business-models
• http://www.novartis.com/esg/access/value-based-pricing
• http://www.novartis.com/esg/access/sub-saharan-africa
• http://www.novartis.com/esg/access/donations
• http://www.novartis.com/esg/access/novartis-access-principles
• http://www.novartis.com/esg/access/novartis-oncology-access
• http://www.novartis.com/esg/access/patents-and-licensing
• http://www.novartis.com/esg/environmental-sustainability
• http://www.novartis.com/esg/environmental-sustainability/climate
• http://www.novartis.com/esg/environmental-sustainability/waste
• http://www.novartis.com/esg/environmental-sustainability/water
• http://www.novartis.com/esg/ethics-risk-and-compliance
• http://www.novartis.com/esg/ethics-risk-and-compliance/ethical-behavior
• http://www.novartis.com/esg/ethics-risk-and-compliance/compliance
• http://www.novartis.com/esg/ethics-risk-and-compliance/human-rights
• http://www.novartis.com/esg/ethics-risk-and-compliance/learning-and-engagement
• http://www.novartis.com/esg/ethics-risk-and-compliance/integrated-risk-assurance
• http://www.novartis.com/esg/global-health
• http://www.novartis.com/esg/global-health/pandemic-preparedness
• http://www.novartis.com/esg/global-health/avoidable-blindness
• http://www.novartis.com/diseases/chagas-disease
• http://www.novartis.com/diseases/leprosy
• http://www.novartis.com/diseases/malaria
• http://www.novartis.com/diseases/sickle-cell-disease
• http://www.novartis.com/esg/index
• http://www.novartis.com/investors/reporting-and-transparency-hub
• http://www.novartis.com/investors/reporting-and-transparency-hub/esg-rating-performance
• http://www.novartis.com/investors/reporting-and-transparency-hub/payments-healthcare-professionals
• http://www.novartis.com/investors/reporting-and-transparency-hub/public-policy
• http://www.novartis.com/investors/reporting-and-transparency-hub/animal-research
• Investors
• http://www.novartis.com/investors/event-calendar
• http://www.novartis.com/investors/financial-data
• http://www.novartis.com/investors/financial-data/annual-results
• http://www.novartis.com/investors/financial-data/quarterly-results
• http://www.novartis.com/investors/financial-data/sec-filings
• http://www.novartis.com/investors/financial-data/product-sales
• http://www.novartis.com/investors/financial-data/fixed-income-securities
• http://www.novartis.com/investors/financial-data/expected-currency-impact
• http://www.novartis.com/investors/share-data-and-analysis
• http://www.novartis.com/investors/share-data-and-analysis/share-monitor
• http://www.novartis.com/investors/share-data-and-analysis/dividend-information
• http://www.novartis.com/investors/share-data-and-analysis/share-ownership
• http://www.novartis.com/investors/share-data-and-analysis/share-overview
• http://www.novartis.com/investors/share-data-and-analysis/return-investment-calculator
• http://www.novartis.com/investors/shareholder-information
• http://www.novartis.com/investors/shareholder-information/general-meetings
• http://www.novartis.com/investors/shareholder-information/american-depositary-receipts-adr
• http://www.novartis.com/investors/shareholder-information/share-buy-back
• http://www.novartis.com/investors/shareholder-information/frequently-asked-questions
• http://www.novartis.com/investors/company-overview
• http://www.novartis.com/investors/company-overview/corporate-governance
• http://www.novartis.com/investors/reporting-and-transparency-hub/reporting-archive
• http://www.novartis.com/news/stay-up-to-date
• Journalists
• All news
• http://www.novartis.com/news/media-library
• http://www.novartis.com/stories
• Events
• Job seekers
• http://www.novartis.com/careers/career-search
• http://www.novartis.com/careers/our-business-functions
• http://www.novartis.com/careers/our-business-functions/careers-research-and-development
• http://www.novartis.com/careers/our-business-functions/careers-operations
• http://www.novartis.com/careers/our-business-functions/careers-commercial-and-sales
• http://www.novartis.com/careers/our-business-functions/careers-global-functions
• http://www.novartis.com/careers/why-novartis
• http://www.novartis.com/careers/career-hub
• http://www.novartis.com/careers/early-careers
• http://www.novartis.com/careers/early-careers/graduates
• http://www.novartis.com/careers/early-careers/students
• http://www.novartis.com/careers/early-careers/us-biomedical-research-internship-programs
• http://www.novartis.com/careers/early-careers/community-exploration-and-learning-lab-cell
• Clinical trials
• Partnering
• http://www.novartis.com/supplier-portal
• http://www.novartis.com/report
• Contacts
• Q4 2025
• Learn more
• http://www.novartis.com/news/media-releases/novartis-remibrutinib-first-therapy-achieve-phase-iii-primary-endpoint-chronic-inducible-urticaria-cindu
• http://www.novartis.com/news/media-releases/novartis-vanrafia-phase-iii-data-support-slowing-kidney-function-decline-patients-iga-nephropathy
• http://www.novartis.com/news/media-releases/novartis-breaks-ground-new-global-biomedical-research-center-san-diego-accelerate-drug-discovery
• Learn more
• Read our full statement
• SpeakUp
• Terms of use
• Privacy
• Cookie settings
• Locations
• Site map
• Open source
• Web accessibility
• http://www.novartis.com/novartis-directory

• Novartis Foundation |
• https://www.novartisfoundation.org/
• https://novartis.willhire.co
• Learn more
• https://www.linkedin.com/company/novartis
• https://www.facebook.com/novartis
• https://x.com/novartis
• https://www.instagram.com/novartis
• https://www.youtube.com/user/novartis

            Domain Name: NOVARTIS.COM
Registrar: MarkMonitor Inc.
Domain Status: client delete prohibited
Domain Status: client transfer prohibited
Domain Status: client update prohibited
Domain Status: server delete prohibited
Domain Status: server transfer prohibited
Domain Status: server update prohibited
Creation Date: 1996-04-02T05:00:00Z
Registry Expiry Date: 2026-11-17T17:29:14Z
Updated Date: 2024-10-16T09:03:36Z
Name Server: A1-254.AKAM.NET
Name Server: A2-66.AKAM.NET
Name Server: A24-65.AKAM.NET
Name Server: A28-67.AKAM.NET
Name Server: A7-64.AKAM.NET
Name Server: A9-65.AKAM.NET
Name Server: DNS1.NOVARTIS.COM
Name Server: DNS2.NOVARTIS.COM
Name Server: DNS3.NOVARTIS.COM
Name Server: DNS4.NOVARTIS.COM
REGISTRAR Contact: MarkMonitor Inc.
>>> Last update of RDAP database: 2026-07-09T07:30:43Z         

			#
# robots.txt
#
# This file is to prevent the crawling and indexing of certain parts
# of your site by web crawlers and spiders run by sites like Yahoo!
# and Google. By telling these "robots" where not to go on your site,
# you save bandwidth and server resources.
#
# This file will be ignored unless it is at the root of your host:
# Used:    http://example.com/robots.txt
# Ignored: http://example.com/site/robots.txt
#
# For more information about the robots.txt standard, see:
# http://www.robotstxt.org/robotstxt.html

User-agent: *
# CSS, JS, Images
Allow: /core/*.css$
Allow: /core/*.css?
Allow: /core/*.js$
Allow: /core/*.js?
Allow: /core/*.gif
Allow: /core/*.jpg
Allow: /core/*.jpeg
Allow: /core/*.png
Allow: /core/*.svg
Allow: /profiles/*.css$
Allow: /profiles/*.css?
Allow: /profiles/*.js$
Allow: /profiles/*.js?
Allow: /profiles/*.gif
Allow: /profiles/*.jpg
Allow: /profiles/*.jpeg
Allow: /profiles/*.png
Allow: /profiles/*.svg
# Directories
Disallow: /core/
Disallow: /profiles/
# Files

Disallow: /web.config
# Paths (clean URLs)

Disallow: /comment/reply/
Disallow: /filter/tips

Disallow: /search/




# Paths (no clean URLs)

Disallow: /index.php/comment/reply/
Disallow: /index.php/filter/tips

Disallow: /index.php/search/




Disallow: /*printable
Disallow: /de-de/sites/novartis_de/files/*FAQ*
Disallow: /de-de/sites/novartis_de/files/*RMP*
Disallow: /de-de/sites/novartis_de/files/*FAQ*
Disallow: /de-de/sites/novartis_de/files/*RMP*
Disallow: /*/spc/*FAQ*
Disallow: /*/spc/*RMP*
Disallow: /*FAQ*
Disallow: /*RMP*

User-agent: GPTBot
Crawl-delay: 2

User-agent: bingbot
Crawl-delay: 2

User-agent: GoogleOther
Crawl-delay: 2
Disallow: /export/site-selector.json        

Teknisk SEO

On-Page SEO

Indhold og UX